These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 26252576)

  • 41. DSEP: A Tool Implementing Novel Method to Predict Side Effects of Drugs.
    Niu SY; Xin MY; Luo J; Liu MY; Jiang ZR
    J Comput Biol; 2015 Dec; 22(12):1108-17. PubMed ID: 26484391
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
    Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
    Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mapping adverse drug reactions in chemical space.
    Scheiber J; Jenkins JL; Sukuru SC; Bender A; Mikhailov D; Milik M; Azzaoui K; Whitebread S; Hamon J; Urban L; Glick M; Davies JW
    J Med Chem; 2009 May; 52(9):3103-7. PubMed ID: 19378990
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Drug target identification using side-effect similarity.
    Campillos M; Kuhn M; Gavin AC; Jensen LJ; Bork P
    Science; 2008 Jul; 321(5886):263-6. PubMed ID: 18621671
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug repositioning by applying 'expression profiles' generated by integrating chemical structure similarity and gene semantic similarity.
    Tan F; Yang R; Xu X; Chen X; Wang Y; Ma H; Liu X; Wu X; Chen Y; Liu L; Jia X
    Mol Biosyst; 2014 May; 10(5):1126-38. PubMed ID: 24603772
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Analysing molecular polar surface descriptors to predict blood-brain barrier permeation.
    Shityakov S; Neuhaus W; Dandekar T; Förster C
    Int J Comput Biol Drug Des; 2013; 6(1-2):146-56. PubMed ID: 23428480
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quantifying biological activity in chemical terms: a pharmacology primer to describe drug effect.
    Kenakin T
    ACS Chem Biol; 2009 Apr; 4(4):249-60. PubMed ID: 19193052
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Exploratory drug safety: a discovery strategy to reduce attrition in development.
    Bass AS; Cartwright ME; Mahon C; Morrison R; Snyder R; McNamara P; Bradley P; Zhou YY; Hunter J
    J Pharmacol Toxicol Methods; 2009; 60(1):69-78. PubMed ID: 19422924
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relating Substructures and Side Effects of Drugs with Chemical-chemical Interactions.
    Zhou B; Zhao X; Lu J; Sun Z; Liu M; Zhou Y; Liu R; Wang Y
    Comb Chem High Throughput Screen; 2020; 23(4):285-294. PubMed ID: 31267865
    [TBL] [Abstract][Full Text] [Related]  

  • 50. WITHDRAWN--a resource for withdrawn and discontinued drugs.
    Siramshetty VB; Nickel J; Omieczynski C; Gohlke BO; Drwal MN; Preissner R
    Nucleic Acids Res; 2016 Jan; 44(D1):D1080-6. PubMed ID: 26553801
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Exploring polypharmacology using a ROCS-based target fishing approach.
    AbdulHameed MD; Chaudhury S; Singh N; Sun H; Wallqvist A; Tawa GJ
    J Chem Inf Model; 2012 Feb; 52(2):492-505. PubMed ID: 22196353
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Using quantitative systems pharmacology for novel drug discovery.
    Pérez-Nueno VI
    Expert Opin Drug Discov; 2015 Dec; 10(12):1315-31. PubMed ID: 26328768
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systematic drug repositioning for a wide range of diseases with integrative analyses of phenotypic and molecular data.
    Iwata H; Sawada R; Mizutani S; Yamanishi Y
    J Chem Inf Model; 2015 Feb; 55(2):446-59. PubMed ID: 25602292
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Failed Pediatric Drug Development Trials.
    Momper JD; Mulugeta Y; Burckart GJ
    Clin Pharmacol Ther; 2015 Sep; 98(3):245-51. PubMed ID: 25963725
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A hierarchical anatomical classification schema for prediction of phenotypic side effects.
    Wadhwa S; Gupta A; Dokania S; Kanji R; Bagler G
    PLoS One; 2018; 13(3):e0193959. PubMed ID: 29494708
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A side effect resource to capture phenotypic effects of drugs.
    Kuhn M; Campillos M; Letunic I; Jensen LJ; Bork P
    Mol Syst Biol; 2010; 6():343. PubMed ID: 20087340
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of drug candidates and repurposing opportunities through compound-target interaction networks.
    Cichonska A; Rousu J; Aittokallio T
    Expert Opin Drug Discov; 2015 Dec; 10(12):1333-45. PubMed ID: 26429153
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Survey of Neonatal Pharmacokinetic and Pharmacodynamic Studies in Pediatric Drug Development.
    Wang J; Avant D; Green D; Seo S; Fisher J; Mulberg AE; McCune SK; Burckart GJ
    Clin Pharmacol Ther; 2015 Sep; 98(3):328-35. PubMed ID: 25975723
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prediction methods and databases within chemoinformatics: emphasis on drugs and drug candidates.
    Jónsdóttir SO; Jørgensen FS; Brunak S
    Bioinformatics; 2005 May; 21(10):2145-60. PubMed ID: 15713739
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Pharmacogenetics and prediction of side effects of drugs].
    Harrak M; Khabbal Y; Amarti A; El Hassouni M; Ouldim K
    Ann Biol Clin (Paris); 2014; 72(4):405-12. PubMed ID: 25119798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.